A Prospective, Multicenter, Randomised, Controlled, Double-blind, Phase 3 Study to Compare Nimotuzumab in Combination With Cisplatin-Vinorelbine , to Cisplatin-Vinorelbine in Combination With Placebo, Followed as Second Line Treatment by Nimotuzumab in Combination With Carboplatin-Paclitaxel Versus Placebo in Combination With Carboplatin-Paclitaxel in the Treatment of Patients With Recurrent and Persistent Cervical Carcinoma

Trial Profile

A Prospective, Multicenter, Randomised, Controlled, Double-blind, Phase 3 Study to Compare Nimotuzumab in Combination With Cisplatin-Vinorelbine , to Cisplatin-Vinorelbine in Combination With Placebo, Followed as Second Line Treatment by Nimotuzumab in Combination With Carboplatin-Paclitaxel Versus Placebo in Combination With Carboplatin-Paclitaxel in the Treatment of Patients With Recurrent and Persistent Cervical Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Vinorelbine
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors ELKendi
  • Most Recent Events

    • 31 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top